BioLife Solutions, Inc. (BLFS): Price and Financial Metrics


BioLife Solutions, Inc. (BLFS): $47.71

0.59 (+1.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BLFS POWR Grades


  • BLFS scores best on the Sentiment dimension, with a Sentiment rank ahead of 70.05% of US stocks.
  • The strongest trend for BLFS is in Quality, which has been heading down over the past 48 weeks.
  • BLFS's current lowest rank is in the Growth metric (where it is better than 11.19% of US stocks).

BLFS Stock Summary

  • BLFS's current price/earnings ratio is 548.84, which is higher than 98.7% of US stocks with positive earnings.
  • With a year-over-year growth in debt of 2,975.31%, Biolife Solutions Inc's debt growth rate surpasses 99.34% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Biolife Solutions Inc is reporting a growth rate of 392.53%; that's higher than 93.99% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Biolife Solutions Inc are PCTY, YELP, LLNW, PCRX, and SGH.
  • BLFS's SEC filings can be seen here. And to visit Biolife Solutions Inc's official web site, go to www.biolifesolutions.com.

BLFS Valuation Summary

  • In comparison to the median Healthcare stock, BLFS's price/sales ratio is 182.82% higher, now standing at 32.1.
  • Over the past 243 months, BLFS's EV/EBIT ratio has gone down 190.6.
  • BLFS's price/sales ratio has moved up 31.2 over the prior 243 months.

Below are key valuation metrics over time for BLFS.

Stock Date P/S P/B P/E EV/EBIT
BLFS 2021-08-31 32.1 5.3 671.3 -190.9
BLFS 2021-08-30 32.1 5.2 670.9 -190.7
BLFS 2021-08-27 30.6 5.0 639.5 -181.6
BLFS 2021-08-26 31.1 5.1 650.8 -184.9
BLFS 2021-08-25 30.6 5.0 639.7 -181.7
BLFS 2021-08-24 25.5 4.2 534.8 -151.3

BLFS Growth Metrics

  • The 4 year cash and equivalents growth rate now stands at 284.98%.
  • The 5 year price growth rate now stands at 597.03%.
  • The 2 year net cashflow from operations growth rate now stands at -35.34%.
BLFS's revenue has moved up $40,293,000 over the prior 15 months.

The table below shows BLFS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 74.056 -4.147 3.538
2021-03-31 52.772 7.778 -20.503
2020-12-31 48.087 6.645 2.45
2020-09-30 41.657 3.385 -11.387
2020-06-30 36.982 5.024 -0.938
2020-03-31 33.763 0.754 16.28

BLFS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BLFS has a Quality Grade of D, ranking ahead of 18.96% of graded US stocks.
  • BLFS's asset turnover comes in at 0.249 -- ranking 138th of 183 Medical Equipment stocks.
  • ZYXI, HJLI, and NURO are the stocks whose asset turnover ratios are most correlated with BLFS.

The table below shows BLFS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.249 0.491 -0.211
2021-03-31 0.269 0.552 -0.611
2020-12-31 0.301 0.571 -0.032
2020-09-30 0.335 0.593 -0.621
2020-06-30 0.383 0.615 -0.137
2020-03-31 0.417 0.654 0.904

BLFS Price Target

For more insight on analysts targets of BLFS, see our BLFS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $62.14 Average Broker Recommendation 1.56 (Moderate Buy)

BLFS Stock Price Chart Interactive Chart >

Price chart for BLFS

BLFS Price/Volume Stats

Current price $47.71 52-week high $60.67
Prev. close $47.12 52-week low $25.20
Day low $46.53 Volume 191,300
Day high $48.11 Avg. volume 350,945
50-day MA $48.90 Dividend yield N/A
200-day MA $41.04 Market Cap 1.94B

BioLife Solutions, Inc. (BLFS) Company Bio


BioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company was founded in 1987 and is based in Bothell, Washington.


BLFS Latest News Stream


Event/Time News Detail
Loading, please wait...

BLFS Latest Social Stream


Loading social stream, please wait...

View Full BLFS Social Stream

Latest BLFS News From Around the Web

Below are the latest news stories about Biolife Solutions Inc that investors may wish to consider to help them evaluate BLFS as an investment opportunity.

BioLife Solutions Appoints Joydeep Goswami, MBA, PhD to Board of Directors

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that Joydeep Goswami, Chief Strategy and Corporate Development Officer at Illumina, will join its board of directors on October 1, 2021. In his role, he is responsible for driving planning, strategic partnerships, and acquisitions. Mr. Goswami replaces Andrew Hinson

Yahoo | September 20, 2021

BioLife Solutions Announces CFO Retirement

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that Roderick de Greef, Chief Financial Officer, plans to retire on December 31, 2021 after a distinguished career with the Company. The Company has retained executive search firm Strawn Arnold to identify candidates to succeed Mr. de Greef. Mr. de Greef will consul

Yahoo | September 15, 2021

CEO Of Biolife Solutions Trades $1.24 Million In Company Stock

Michael Rice, CEO at Biolife Solutions (NASDAQ:BLFS), made a large buy and sell of company shares on September 9, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Michael Rice purchased 22,922 Biolife Solutions shares at a price of $1.64 per share for a total of $37,592 on September 9. They then sold their shares on multiple transactions in the open market. They sold at prices ranging from $52.50 to $52.59 to raise a total

Yahoo | September 10, 2021

Is There Now An Opportunity In BioLife Solutions, Inc. (NASDAQ:BLFS)?

BioLife Solutions, Inc. ( NASDAQ:BLFS ), is not the largest company out there, but it saw a significant share price...

Yahoo | September 10, 2021

Why Shares in BioLife Solutions Jumped 24.4% in August

The company, which specializes in cold-storage solutions for biotechs, had a hot month.

The Motley Fool | September 7, 2021

Read More 'BLFS' Stories Here

BLFS Price Returns

1-mo -14.21%
3-mo 6.93%
6-mo 33.57%
1-year 82.80%
3-year 172.16%
5-year 2,478.92%
YTD 19.60%
2020 146.54%
2019 34.50%
2018 100.50%
2017 272.67%
2016 -25.81%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9741 seconds.